For patients receiving Faslodex in combination with Ibrance, the median overall survival has been observed to be 34.9 months. This figure represents the point at which half of the patients in the study group were still alive, offering a key indicator of treatment efficacy.
Understanding Median Overall Survival
When discussing the life expectancy of individuals with advanced cancer receiving specific treatments like Faslodex, the term "median overall survival" (mOS) is commonly used. This refers to the length of time from the start of treatment or diagnosis for a group of patients, at which half of the patients are still alive. It is a critical measure in clinical trials for evaluating the effectiveness of a therapy.
Key Survival Data
Clinical studies have provided important insights into the median overall survival for patients treated with Faslodex, specifically when administered alongside Ibrance. This combination therapy has shown a significant benefit compared to a placebo group (which would typically receive standard endocrine therapy without the added targeted drug).
Here is a summary of the survival data:
| Treatment Group | Median Overall Survival (Months) | Median Follow-up (Months) |
|---|---|---|
| Ibrance Plus Faslodex | 34.9 | 44.8 |
| Placebo Group | 28.0 | - |
- Ibrance Plus Faslodex: Patients receiving this combination experienced a median overall survival of 34.9 months. This data was observed after a median follow-up period of 44.8 months.
- Placebo Group: In comparison, patients in the placebo group had a median overall survival of 28 months.
Context of Treatment
It's important to note that Faslodex (fulvestrant) is typically used to treat hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer. It functions as an estrogen receptor antagonist, blocking the effects of estrogen on cancer cells. The data provided specifically reflects its use in combination with Ibrance (palbociclib), a cyclin-dependent kinase (CDK4/6) inhibitor, which is a common and effective regimen for this type of breast cancer. The combination therapy has shown improved outcomes compared to Faslodex alone or other standard treatments.
